期刊文献+

他克莫司与环磷酰胺联合激素治疗特发性膜性肾病的疗效比较 被引量:24

Efficacy and safety of tacrolimus versus cyclosporine in adults with idiopathic membranous nephropathy
下载PDF
导出
摘要 目的:比较他克莫司(Tacrolimus,TL)与环磷酰胺(Cyclophosphamide,CTX)联合激素治疗特发性膜性肾病(idiopathic membranous ne-phropathy,IMN)的疗效及安全性。方法:选择本院原发性肾病综合征经肾活检确诊为IMN的30例患者,排除继发性膜性肾病,随机分为两组,分别给予TL联合激素治疗[TL组,0.07~0.1mg.kg-1.d-1,n=15]或CTX联合激素治疗[CTX组,0.75~1.0g/m2,1次/月,n=15],疗程为6个月。主要观察治疗前后24小时尿蛋白、血清白蛋白、血脂、血糖、肝肾功的变化和不良反应发生率,以及治疗后的完全缓解率、部分缓解率。结果:TL或CTX治疗6个月后疗效指标均出现明显的改善。TL组1月后24小时蛋白尿、血清白蛋白和血脂出现明显缓解,而CTX组2月后才出现明显缓解。治疗6个月后TL组完全缓解率高于CTX组(40.0%vs 13.3%),总缓解率高于CTX组(93.3%vs 60.0%)。TL组副作用主要有:胃肠不适2例(13.3%),血糖升高1例(6.7%)、细菌性肺炎1例(6.7%)、带状疱疹1例(6.7%),血清肌酐升高1例(6.7%)、轻度肝转氨酶升高1例(6.7%)、脱发2例(13.3%)。CTX组的副作用:胃肠道不适2例(13.3%),肺部感染2例(13.3%),带状疱疹1例(6.7%),骨髓抑制2例(13.3%),肝功能损害3例(20.0%),化学性膀胱炎2例(13.3%),脱发6例(40.0%)。结论:TL联合激素治疗膜性肾病是有效和安全的。与CTX相比,TL能迅速缓解膜性肾病患者蛋白尿,并有更高的IMN缓解率。 AIM: To compare the clinical effi- cacy and side-effects in patients with idiopathic membranous nephropathy who received Tacroli- mus (TL) or Cyclophosphamide (CTX) METHODS: 30 patients with primary nephrotie syndrome admitted to our hospital, diagnosed by renal biopsy in IMN, excluded in the diagnosis of secondary membranous nephropathy, were randomly divided into Taerolimus combined with glucoeorticoid treatment (TL group, 0.07 - 0.1 mg · kg-1 · d-1 , n = 15) or CWX combined with glucocorticoid treatment ( CTX group, 0.75-1.0 g/m2 body surface area, every month for 6 months, n= 15) . All patients received variable doses of prednisolone concomitant with TL or CTX therapy, as a dose o( 1.0 mg · kg-1 · d-1 initially and maintained at 0.2-- 0.3 mg· kg^-1 · d^-1. The planned duration of study to assess treatment efficacy was at least 6 months. The effect of TL was observed by the change of 24 h urinary protein, serum albumin, Blood lipid, Blood glucose, liver and kidney function and its adverse effects in each group, and complete response rate and partial remission rate. RESULTS: Significant clinical improvement in IMN patients was observed after TL or CTX treatment and the most noticeable effect was found at 6 months of therapy. TL significantly alleviate proteinuria, serum albumin and blood lipids a month later, while CTX need two months. At the end of 6 months, the complete remission rate and total remission rate in TL group was significantly higher than these in the CTX group (40.0% vs 13.3%, 93.3% vs 60.0%, respectively). Adverse effects in the TL group : gastrointestinal discomfort (13.3%), glucose intolerance (6.7%), bacteri- al pneumonia (13.3%), shingles (6.7%), ser- um creatinine increased (6.7 %), transaminase increased (6. 7%), alopecia (13.3%). In the CTX group : gastrointestinal discomfort (13.3%), bacterial pneumonia(13.3%), shin- gles (6.7%), myelosuppression (13.3%), transaminase increased (20.0 %), chemical cys- titis (13.3%), alopecia (40.0K). CONCLU- SION : The study suggests that a 6-month course of TL is a safe and effective treatment of IMN. As compared with CTX treatment, TL possibly results in a faster resolution of proteinuria and a higher remission rate of IMN.
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第7期797-801,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 第三军医大学临床科研基金(2010年)
关键词 他克莫司 环磷酰胺 特发性膜性肾病 治疗 Tacrolimus Cyclophosphamide Idiopathic membranous nephropathy Treatment
  • 相关文献

参考文献15

  • 1McQuarrie EP, Stirling CM, Geddes CC. Idiopathic membranous nephropathy and nephrotic syndrome outcome in the era of evidence-based therapy[J]. Nephrol Dial Transplant, 2012,2 (7) : 235 - 242.
  • 2Quaglia M, Stratta P. Idiopathic membranous ne- phropathy: management strategies [J].Drugs, 2009, 69(10) : 1303-1317.
  • 3Ji SM, Li LS, Sha GZ, et al. Conversion from cy- closporine to tacrolimus for chronic allograft ne- phropathy[J]. Transplant Proc, 2007, 39(5) :1402 -1405.
  • 4Bowman L J, Brennan DC. The role of tacrolimus in renal transplantation [J].Expert Opin Pharmacoth- er,2008, 9(4) :635-643.
  • 5黄云剑,王梓华,张静波,陈枫,赵景宏.他克莫司与环孢霉素治疗单纯性V型狼疮性肾炎的疗效比较[J].临床军医杂志,2009,37(3):364-367. 被引量:12
  • 6Ponticelli C, Zucchelli P, Passerini P, et al. A 10- year follow-up of a randomized study with methyl- prednisolone and chlorambucil in membranous ne- phropathy[J]. Kidney Int, 1995, 48(S):1600- 1604.
  • 7Ruggenenti P, Cravedi P, Remuzzi G. Latest treat- ment strategies for membranous nephropathy[J]. Expert Opin Pharmacother, 2007, 8 (18) : 3159 - 3171.
  • 8Ruggenenti P, Cravedi P, Remuzzi G. Latest treat ment strategies for membranous nephropathy [J]. Expert Opin Pharmacother, 2007, 8 (18) : 3159 - 3171.
  • 9Aaltonen S, Honkanen E. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy[J]. Nephrol Dial Transplant, 2011,26(9) :2871-2877.
  • 10Takahashi S, Hiromura K, Sakurai N, et al. Effi- cacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis [J]. Mod Rheumatol, 2011,21(3) :282-289.

二级参考文献15

  • 1Aran AA,Putterman C.Treatment of lupus nephritis:facing the era of immunotherapy[J].Panminerva Med,2008,50(3):235-245.
  • 2Houssiau FA,Ginzler EM.Current treatment of lupus nephritis[J].Lupus,2008,17(5):426-430.
  • 3Bowman LJ,Brennan DC.The role of tacrolimus in renal transplantation[J].Expert Opin Pharmacother,2008,9(4):635-643.
  • 4Ji SM,Li LS,Sha GZ,et al.Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy[J].Transplant Proc,2007,39(5):1402-1405.
  • 5Ballarin J,Poveda R,Ara J,et al.Treatment of idiopathic membranous nephropathy with the combination of steroids,tacrolimus and mycophenolate mofetil:results of a pilot study[J].Nephrol Dial Transplant,2007,22(11):3196-3201.
  • 6Praga M,Barrio V,Juarez GF,et al.Tacrolimus monotherapy in membranous nephropathy:a randomized controlled trial[J].Kidney Int,2007,71(9):924-930.
  • 7Mok CC,Tong KH,To CH,et al.Tacrolimus for induction therapy of diffuse proliferative lupus nephritis:an open-labeled pilot study[J].Kidney Int,2005,68(2):813-817.
  • 8Maruyama M,Yamasaki Y,Sada K,et al.Good response of membranous lupus nephritis to tacrolimus[J].Clin Nephrol,2006,65(4):276-279.
  • 9Tanaka H,Oki E,Tsugawa K,et al.Effective treatment of young patients with pediatric-onset,long-standing lupus nephritis with tacrolimus given as a single daily dose:an open-label pilot study[J].Lupus,2007,16(11):896-900.
  • 10Bao H,Liu ZH,Xie HL,et al.Successful treatment of class V+IV lupus nephritis with multitarget therapy[J].J Am Soc Nephrol,2008,19(10):2001-2010.

共引文献11

同被引文献218

  • 1张宜苗,初荣,柴立军,王素霞,刘刚.微小病变肾病患者恢复期足突超微结构的改变[J].中华临床医师杂志(电子版),2011,5(19):5674-5679. 被引量:1
  • 2刘喜红,易著文,黄丹琳,陈丹,关凤军,曹艳.中西医结合治疗原发性肾病综合征的系统评价[J].医学临床研究,2007,24(4):549-554. 被引量:15
  • 3Houssiau FA, Lefebvre C, Vanden BM, et al. Serum interleukin 10 titiers in systemic lupus erythematosus reflect disease activity [ J ]. Lupus, 1995,4 (5) : 393 -395.
  • 4Israni AK, Riad SM, Leduc R, et al. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation:a lesson learned from DeKAF Genomies [J]. Transpl Int, 2013,26(10) : 982-989.
  • 5Tsuchiya T, Ishida H, Tanabe T, et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once- daily and twice-daily in living kidney transplantation : prospective trial in once-daily versus twice-daily tacrolimus [J]. Transplantation, 2013,96(2) : 198-204.
  • 6Kurasawa T, Nagasawa H, Nishi E, et al. Successful treatment of class IV+V lupus nephritis with combination therapy of high- dose corticosteroids, tacrolimus and intravenous cyclophosphamide [J]. Intern Med, 2013,52(10) : 1125-1130.
  • 7Praga M, Barrio V, Jurrez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trim [Jl. Kidney Int, 2007,71 (9) : 924-930.
  • 8Xu J, Zhang W, Xu Y, et M. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial [J]. Contrib Nephml, 2013,181 : 152-162.
  • 9Chen M, Li H, Li XY, et al. Tacrolimus combined with orticostemids in treatment of nephrotic idiopathic membranous nephropathy: amulticenter randomized controlled trial [J].Am J Med Sci, 2010,339(3) :233-238.
  • 10He L, Peng Y, Liu H, et al. Treatment of idiopathic aembranous nephropathy with combination of low-dose :acrolimus and cortieosteroids [J]. J Nephrol, 2013,26 (3): 564-571.

引证文献24

二级引证文献200

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部